Benlysta: New Lupus Medication

Ruzanna Harutyunyan's picture
Advertisement

Human Genome Sciences and GlaxoSmithKline announced positive results from their Phase-III, double-blind, placebo-controlled lupus clinical trial.

This 52-week study, also known as BLISS-52, enrolled 865 patients in 13 countries outside North America and randomized active lupus patients to 10mg/kg active drug (Belimumab, also known as Benlysta), 1 mg/kg active drug, or placebo (not containing active drug) in addition to their standard lupus medications.

Patients had to fulfill the American College of Rheumatology lupus criteria, have active lupus, and remain on a stable treatment regimen (excluding other biologic therapies or cyclophosphamide) in order to be eligible for the trial. Patients with severe lupus kidney disease and lupus-related neurologic problems were excluded. The study medication was given intravenously (through the veins) two weeks apart for the first two doses, and then every four weeks.

The study was successful in meeting its predetermined primary outcome, which was the percentage of patients with improvement by four or more points in their SELENA SLEDAI score (a validated composite clinical index measuring lupus activity in various organs) without worsening in two other clinical instruments for disease activity (physician global assessment (PGA) and BILAG (another clinical index to measure disease activity).

The response rates were 57.6%, 51.7% and 43.6% for Benlysta 10mg/kg, 1 mg/kg, and placebo, respectively (the response rates were significantly better in the active drug arms). In addition to improvement in various clinical measurements of disease activity, patients were also able to reduce steroid dosages. Notably, the drug was tolerated well and the safety profile, including the infection rate, was comparable to the placebo arm.

The Medication: Benlysta

Benlysta is a fully human monoclonal antibody that blocks the activity of a protein called B lymphocyte stimulator (BLyS). This protein has the ability to activate B-cells to produce autoantibodies (antibodies against self), which promote tissue damage in lupus.

Advertisement

What does this mean for patients and their physicians?

The study findings show that Benlysta has the potential to become the first new approved lupus drug in decades for people living with lupus. The findings are exciting for both lupus patients and physicians, given that there is currently a paucity of medications that are both safe and effective for lupus.

Based on the information we have from the study, Benlysta is likely to be used to treat patients with lupus that have an inadequate response to one or more of currently available drugs, such as hydroxychloroquine, mycophenolate mofetil, and/or azathioprine. It is unknown at this point whether Benlysta will also be effective in Lupus Nephritis and lupus affecting the nervous system, two of the most severe manifestations of lupus.

The developer of Benlysta, Human Genome Sciences, is sharing development and marketing of the drug with GlaxoSmithKline. They are awaiting results from a second Phase-III trial (BLISS-76, conducted in North America and Europe, in which Hospital for Special Surgery is one of the participating centers), due in November 2009. If those results are also positive for Benlysta, the companies are planning to apply for regulatory approval in the first half of next year.

Kyriakos A. Kirou, MD, FACR
Assistant Attending Physician, Hospital for Special Surgery
Assistant Professor of Medicine, Weill Cornell Medical College
Clinical Co-Director, Mary Kirkland Center for Lupus Care

Doruk Erkan, MD
Assistant Attending Rheumatologist, Hospital for Special Surgery
Assistant Professor of Medicine, Weill Cornell Medical College
Associate Physician-Scientist, Barbara Volcker Center for Women and Rheumatic Disease

Pretima Persad, MPH
Mary Kirkland Center for Lupus Care
Hospital for Special Surgery

Reprinted from www.hss.edu

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement

Comments

Mohamed Faghihi sister sick with systemic lupus erythematosus did not find treatment and read BENLYSTA I hope that this treatment addresses the sister